Impact of Cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
Tacrolimus pharmacokinetic characteristics vary greatly among individuals. Tacrolimus is a substrate of cytochrome p450 (CYP), of subfamily CYP3A. CYP3A activity is the sum of the activities of the family of CYP3A genes, including CYP3A5. Subjects with the CYP3A5*1/*1 genotype express large amounts...
Gespeichert in:
| Veröffentlicht in: | Transplantation 2003-10, Vol.76 (8), p.1233-1235 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1235 |
|---|---|
| container_issue | 8 |
| container_start_page | 1233 |
| container_title | Transplantation |
| container_volume | 76 |
| creator | THERVET, Eric ANGLICHEAU, Dany KING, Barry SCHLAGETER, Marie-Hélène CASSINAT, Bruno BEAUNE, Philippe LEGENDRE, Christophe DALY, Ann K |
| description | Tacrolimus pharmacokinetic characteristics vary greatly among individuals. Tacrolimus is a substrate of cytochrome p450 (CYP), of subfamily CYP3A. CYP3A activity is the sum of the activities of the family of CYP3A genes, including CYP3A5. Subjects with the CYP3A5*1/*1 genotype express large amounts of CYP3A5. Heterozygotes (genotype CYP3A5*1/*3) also express the enzyme. We postulated that CYP3A5 polymorphism is associated with tacrolimus pharmacokinetic variations.
CYP3A5 genotype was evaluated in 80 renal transplant recipients and correlated with the daily tacrolimus dose and concentration-to-dose ratio.
The frequency of the homozygous CYP3A5*1 genotype (CYP3A5*1/*1) was 5%, and 11% of subjects were heterozygous (CYP3A5*1/*3). The mean doses required to obtain the targeted concentration-to-dose ratio were significantly lower in patients with the CYP3A5*1/*1 genotype.
Determination of CYP3A5 genotype is predictive of the dose of tacrolimus in renal transplant recipients and may help to determine the initial daily dose needed by individual patients for adequate immunosuppression without excess nephrotoxicity. |
| doi_str_mv | 10.1097/01.TP.0000090753.99170.89 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_14578760</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>14578760</sourcerecordid><originalsourceid>FETCH-LOGICAL-p237t-caf58866401a1ee0fb578b8c355c5c7e6b7bab178d690a00fd6be97c820b3d0c3</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRS0EoqXwC8gsWCaM6_iRZVXxqFSJLsq6sh2HGiW2FbuLfgD_TcpDzGY0c89czQxCdwRKArV4AFJuNyWcogbBaFnXREAp6zM0JYxWBQcJ52gKUJGCUCom6CqljxFnVIhLNCEVE1JwmKLPVR-VyTi0eHnMweyH0Fu8qRhgumD43XqbncExdMc-DHHvUo-Dx1mZIXSuPyTchGQTVr7BJnhjfR5UdsEXORQnCX-X2Hk8WK86PMo-xU75PDaMi26cSNfoolVdsje_eYbenh63y5di_fq8Wi7WRZxTkQujWiYl5xUQRayFVo9naGkoY4YZYbkWWmkiZMNrUABtw7WthZFz0LQBQ2fo9sc3HnRvm10cXK-G4-7vHyNw_wuoZFTXjssal_45NueS0op-AQfCc6w</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Impact of Cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>THERVET, Eric ; ANGLICHEAU, Dany ; KING, Barry ; SCHLAGETER, Marie-Hélène ; CASSINAT, Bruno ; BEAUNE, Philippe ; LEGENDRE, Christophe ; DALY, Ann K</creator><creatorcontrib>THERVET, Eric ; ANGLICHEAU, Dany ; KING, Barry ; SCHLAGETER, Marie-Hélène ; CASSINAT, Bruno ; BEAUNE, Philippe ; LEGENDRE, Christophe ; DALY, Ann K</creatorcontrib><description>Tacrolimus pharmacokinetic characteristics vary greatly among individuals. Tacrolimus is a substrate of cytochrome p450 (CYP), of subfamily CYP3A. CYP3A activity is the sum of the activities of the family of CYP3A genes, including CYP3A5. Subjects with the CYP3A5*1/*1 genotype express large amounts of CYP3A5. Heterozygotes (genotype CYP3A5*1/*3) also express the enzyme. We postulated that CYP3A5 polymorphism is associated with tacrolimus pharmacokinetic variations.
CYP3A5 genotype was evaluated in 80 renal transplant recipients and correlated with the daily tacrolimus dose and concentration-to-dose ratio.
The frequency of the homozygous CYP3A5*1 genotype (CYP3A5*1/*1) was 5%, and 11% of subjects were heterozygous (CYP3A5*1/*3). The mean doses required to obtain the targeted concentration-to-dose ratio were significantly lower in patients with the CYP3A5*1/*1 genotype.
Determination of CYP3A5 genotype is predictive of the dose of tacrolimus in renal transplant recipients and may help to determine the initial daily dose needed by individual patients for adequate immunosuppression without excess nephrotoxicity.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/01.TP.0000090753.99170.89</identifier><identifier>PMID: 14578760</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Adult ; Biological and medical sciences ; Combined surgery. Multiple transplantations ; Cytochrome P-450 CYP3A ; Cytochrome P-450 Enzyme System - genetics ; Dose-Response Relationship, Drug ; Female ; Gene Frequency ; Genotype ; Humans ; Immunosuppressive Agents - administration & dosage ; Kidney Transplantation ; Male ; Medical sciences ; Middle Aged ; Osmolar Concentration ; Polymorphism, Genetic ; Predictive Value of Tests ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Tacrolimus - administration & dosage</subject><ispartof>Transplantation, 2003-10, Vol.76 (8), p.1233-1235</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15268334$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14578760$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>THERVET, Eric</creatorcontrib><creatorcontrib>ANGLICHEAU, Dany</creatorcontrib><creatorcontrib>KING, Barry</creatorcontrib><creatorcontrib>SCHLAGETER, Marie-Hélène</creatorcontrib><creatorcontrib>CASSINAT, Bruno</creatorcontrib><creatorcontrib>BEAUNE, Philippe</creatorcontrib><creatorcontrib>LEGENDRE, Christophe</creatorcontrib><creatorcontrib>DALY, Ann K</creatorcontrib><title>Impact of Cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>Tacrolimus pharmacokinetic characteristics vary greatly among individuals. Tacrolimus is a substrate of cytochrome p450 (CYP), of subfamily CYP3A. CYP3A activity is the sum of the activities of the family of CYP3A genes, including CYP3A5. Subjects with the CYP3A5*1/*1 genotype express large amounts of CYP3A5. Heterozygotes (genotype CYP3A5*1/*3) also express the enzyme. We postulated that CYP3A5 polymorphism is associated with tacrolimus pharmacokinetic variations.
CYP3A5 genotype was evaluated in 80 renal transplant recipients and correlated with the daily tacrolimus dose and concentration-to-dose ratio.
The frequency of the homozygous CYP3A5*1 genotype (CYP3A5*1/*1) was 5%, and 11% of subjects were heterozygous (CYP3A5*1/*3). The mean doses required to obtain the targeted concentration-to-dose ratio were significantly lower in patients with the CYP3A5*1/*1 genotype.
Determination of CYP3A5 genotype is predictive of the dose of tacrolimus in renal transplant recipients and may help to determine the initial daily dose needed by individual patients for adequate immunosuppression without excess nephrotoxicity.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Combined surgery. Multiple transplantations</subject><subject>Cytochrome P-450 CYP3A</subject><subject>Cytochrome P-450 Enzyme System - genetics</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Gene Frequency</subject><subject>Genotype</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Kidney Transplantation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Osmolar Concentration</subject><subject>Polymorphism, Genetic</subject><subject>Predictive Value of Tests</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Tacrolimus - administration & dosage</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtOwzAQRS0EoqXwC8gsWCaM6_iRZVXxqFSJLsq6sh2HGiW2FbuLfgD_TcpDzGY0c89czQxCdwRKArV4AFJuNyWcogbBaFnXREAp6zM0JYxWBQcJ52gKUJGCUCom6CqljxFnVIhLNCEVE1JwmKLPVR-VyTi0eHnMweyH0Fu8qRhgumD43XqbncExdMc-DHHvUo-Dx1mZIXSuPyTchGQTVr7BJnhjfR5UdsEXORQnCX-X2Hk8WK86PMo-xU75PDaMi26cSNfoolVdsje_eYbenh63y5di_fq8Wi7WRZxTkQujWiYl5xUQRayFVo9naGkoY4YZYbkWWmkiZMNrUABtw7WthZFz0LQBQ2fo9sc3HnRvm10cXK-G4-7vHyNw_wuoZFTXjssal_45NueS0op-AQfCc6w</recordid><startdate>20031027</startdate><enddate>20031027</enddate><creator>THERVET, Eric</creator><creator>ANGLICHEAU, Dany</creator><creator>KING, Barry</creator><creator>SCHLAGETER, Marie-Hélène</creator><creator>CASSINAT, Bruno</creator><creator>BEAUNE, Philippe</creator><creator>LEGENDRE, Christophe</creator><creator>DALY, Ann K</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20031027</creationdate><title>Impact of Cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients</title><author>THERVET, Eric ; ANGLICHEAU, Dany ; KING, Barry ; SCHLAGETER, Marie-Hélène ; CASSINAT, Bruno ; BEAUNE, Philippe ; LEGENDRE, Christophe ; DALY, Ann K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p237t-caf58866401a1ee0fb578b8c355c5c7e6b7bab178d690a00fd6be97c820b3d0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Combined surgery. Multiple transplantations</topic><topic>Cytochrome P-450 CYP3A</topic><topic>Cytochrome P-450 Enzyme System - genetics</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Gene Frequency</topic><topic>Genotype</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Kidney Transplantation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Osmolar Concentration</topic><topic>Polymorphism, Genetic</topic><topic>Predictive Value of Tests</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Tacrolimus - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>THERVET, Eric</creatorcontrib><creatorcontrib>ANGLICHEAU, Dany</creatorcontrib><creatorcontrib>KING, Barry</creatorcontrib><creatorcontrib>SCHLAGETER, Marie-Hélène</creatorcontrib><creatorcontrib>CASSINAT, Bruno</creatorcontrib><creatorcontrib>BEAUNE, Philippe</creatorcontrib><creatorcontrib>LEGENDRE, Christophe</creatorcontrib><creatorcontrib>DALY, Ann K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>THERVET, Eric</au><au>ANGLICHEAU, Dany</au><au>KING, Barry</au><au>SCHLAGETER, Marie-Hélène</au><au>CASSINAT, Bruno</au><au>BEAUNE, Philippe</au><au>LEGENDRE, Christophe</au><au>DALY, Ann K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>2003-10-27</date><risdate>2003</risdate><volume>76</volume><issue>8</issue><spage>1233</spage><epage>1235</epage><pages>1233-1235</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>Tacrolimus pharmacokinetic characteristics vary greatly among individuals. Tacrolimus is a substrate of cytochrome p450 (CYP), of subfamily CYP3A. CYP3A activity is the sum of the activities of the family of CYP3A genes, including CYP3A5. Subjects with the CYP3A5*1/*1 genotype express large amounts of CYP3A5. Heterozygotes (genotype CYP3A5*1/*3) also express the enzyme. We postulated that CYP3A5 polymorphism is associated with tacrolimus pharmacokinetic variations.
CYP3A5 genotype was evaluated in 80 renal transplant recipients and correlated with the daily tacrolimus dose and concentration-to-dose ratio.
The frequency of the homozygous CYP3A5*1 genotype (CYP3A5*1/*1) was 5%, and 11% of subjects were heterozygous (CYP3A5*1/*3). The mean doses required to obtain the targeted concentration-to-dose ratio were significantly lower in patients with the CYP3A5*1/*1 genotype.
Determination of CYP3A5 genotype is predictive of the dose of tacrolimus in renal transplant recipients and may help to determine the initial daily dose needed by individual patients for adequate immunosuppression without excess nephrotoxicity.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>14578760</pmid><doi>10.1097/01.TP.0000090753.99170.89</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1337 |
| ispartof | Transplantation, 2003-10, Vol.76 (8), p.1233-1235 |
| issn | 0041-1337 1534-6080 |
| language | eng |
| recordid | cdi_pubmed_primary_14578760 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Biological and medical sciences Combined surgery. Multiple transplantations Cytochrome P-450 CYP3A Cytochrome P-450 Enzyme System - genetics Dose-Response Relationship, Drug Female Gene Frequency Genotype Humans Immunosuppressive Agents - administration & dosage Kidney Transplantation Male Medical sciences Middle Aged Osmolar Concentration Polymorphism, Genetic Predictive Value of Tests Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Tacrolimus - administration & dosage |
| title | Impact of Cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A22%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Cytochrome%20P450%203A5%20genetic%20polymorphism%20on%20tacrolimus%20doses%20and%20concentration-to-dose%20ratio%20in%20renal%20transplant%20recipients&rft.jtitle=Transplantation&rft.au=THERVET,%20Eric&rft.date=2003-10-27&rft.volume=76&rft.issue=8&rft.spage=1233&rft.epage=1235&rft.pages=1233-1235&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/01.TP.0000090753.99170.89&rft_dat=%3Cpubmed_pasca%3E14578760%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/14578760&rfr_iscdi=true |